Raymond James raised the firm’s price target on Intercept Pharmaceuticals to $28 from $26 and keeps an Outperform rating on the shares following the Q4 report.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ICPT:
- Intercept price target raised to $18 from $17 at SVB Securities
- Intercept price target raised to $19 from $17 at RBC Capital
- Intercept sees FY23 Ocaliva net sales $310M-$340M
- Intercept reports Q4 EPS (50c), consensus (16c)
- Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance